Associate Territory Manager - Trauma
About the job
- A Bachelor's degree in any discipline is required.
- At least 1 year of experience in a customer-facing, sales, or healthcare-related role is required.
- Ability to work in hospital environments, including operating theatres, is required.
- A current valid driver's licence is required.
- Fluency in English is required.
- Support surgeons in theatre during Trauma procedures.
- Provide clinical and technical guidance to hospital teams.
- Build relationships with surgeons, nurses, and theatre staff.
- Partner with the Territory Manager on business planning and account strategy.
- Identify opportunities to grow the Trauma portfolio across the region.
- Deliver education and in-servicing to hospital teams.
- Manage instruments, set preparation, and case logistics.
- Stay current on new products, techniques, and industry developments.
- A tertiary qualification in an allied health field, such as nursing, physiotherapy, or exercise science.
- At least 1 year of experience in clinical, technical, or medical sales environments.
- Experience working toward sales targets or key performance indicators in any industry.
About the company
Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kalamazoo, Michigan
Founded
1941
Get referred to Stryker
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 organic sales grew 9%, showing resilient hospital demand across businesses.
- Mako recorded its best-ever second quarter installations in the U.S. and internationally.
- Stryker signed ZuriMED and bought AVS, deepening shoulder and peripheral vascular pipelines.
What critics are saying
- A 2026 cyber incident disrupted production, delayed backorders, and exposed operational fragility.
- Peripheral Vascular supply problems caused lost sales in Q2 2026 and linger into Q3.
- Lakeland closures continue through mid-2027, signaling restructuring pressure and execution drag.
What makes Stryker unique
- Mako surpassed 2.5 million procedures worldwide, reinforcing robotics leadership in orthopedics.
- SportSuite Vision won FDA De Novo authorization for Apple Vision Pro surgical use.
- Stryker combined Ortho Tech in 2026, tightening workflow across Mako and instruments.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical & prescription plans
Supplemental health benefits
Flexible Spending accounts
Employee Assistance Program
Short-term & long-term disability
Tuition reimbursement
401(k) plan
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%Stryker (NYSE:SYK) shares have fallen 20% over the past six months to $277.82, while the S&P 500 gained 12.8%. The medical device maker develops orthopedic, surgical, neurotechnology, and patient care products that reach over 150 million patients a year. Organic revenue, which excludes acquisitions, divestitures, and currency swings, grew an average of 9.2% year-on-year over the past two years. That suggests Stryker can expand without costly acquisitions. Revenue over the past 12 months was $25.84 billion. Its scale gives it leverage with suppliers in a heavily regulated, competitive market. Free cash flow margin rose 6.5 percentage points over five years to 18.2% for the trailing 12 months. After the drop, the stock trades at 17.4× forward earnings.
Stryker announced a $400 million (£300 million) preferred equity investment in CMR Surgical on Monday. The money will support innovation and global expansion of CMR's Versius surgical robotics portfolio. The deal also gives Stryker an exclusive option to acquire 100% of CMR Surgical.
Stryker has launched Mako 4 SmartRobotics in India, introducing the fourth generation of its robotic-arm assisted technology for joint replacement procedures. The system combines patient-specific planning, robotic technology, and haptic guidance for total knee, partial knee, and total hip applications. Mako 4 uses 3D CT-based planning with AccuStop haptic technology to support surgeons in planning and executing procedures according to individual patient anatomy. The platform provides real-time intraoperative guidance for greater precision during joint replacement procedures. The global Mako platform has supported more than 2.5 million procedures across 47 countries. Aman Rishi, Stryker's vice president and general manager for India, said the launch aims to raise the standard of care and expand access for joint replacement patients nationwide.
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) - Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease. “This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease,” said Kevin Lobo, Chair and CEO, Stryker. “By integrating AVS’s innovative CO₂-generated pressure wave technology with Stryker’s scale and resources, we are well-positioned to deliver solutions that support physicians and patient outcomes.” The addition of an IVL platform will strengthen Stryker’s impact in peripheral vascular solutions. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products
Stryker is launching Prophecy Surgical Planning for its Incompass Total Ankle System and introducing Hoffmann LRF smartHEX at the 2026 American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle. Prophecy has supported patient-specific planning for more than 100,000 ankle cases over 14 years. The platform now offers surgeons 3D visualisation and both resect-through and pin-through fixation options within a single connected platform. The Incompass Total Ankle System was designed using insights from Prophecy and Stryker's orthopaedic modelling analytics, incorporating real-world anatomy into the implant design. Hoffmann LRF smartHEX expands Stryker's limb reconstruction portfolio with new rings, struts and frame components. It includes a mobile app and planning software designed to enhance frame versatility and support connected care for complex deformity correction.